Akita-Based UMN Pharma Uses Insects Cells And Shortens Flu Vaccine Production Timeline
This article was originally published in PharmAsia News
Akita, Japan-based biopharmaceutical company UMN Pharma announced May 26 Japan's Pharmaceuticals and Medical Device Agency cleared the vaccine for clinical trials, and UMN plans to start the H5N1 flu vaccine trials on 125 men in June. Unlike other vaccines, UMN uses insects cells to culture the virus DNA. The process enables the company to shorten production time from currently half a year to two months. (Click here for more - Japanese language
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.